07/11/2018 14:00:00

GeoVax Presenting at Upcoming Scientific Conferences

Plug & Play Platform Continues to be Recognized for Distinct Benefits

ATLANTA, GA, Nov. 07, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that it will be represented during presentations at the following upcoming scientific conferences.

Fourth International Conference on Vaccines Research and Development, Baltimore, Nov. 12-14

Farshad Guirakhoo, PhD, GeoVax Chief Scientific Officer, will deliver an oral presentation entitled, Development of Vaccines for Infectious Diseases and Cancer Using a Novel MVA-VLP “Plug & Play” Vector Platform; Preclinical Efficacy for Ebola, Lassa Fever and Zika as examples for single dose vaccines. In this talk, the most relevant single-dose vaccine efficacy data, including characterization of humoral and T cell responses, for three different pathogens (Ebola, Lassa and Zika) will be presented as examples for a broad utility of the platform for other indications such as malaria, HPV, HBV and cancer immunotherapy. Dr. Guirakhoo will also serve as Chair for the conference breakout session on Emerging and Re-emerging Diseases on November 14.

World Vaccine & Immunotherapy Congress, San Diego, Nov. 28-30

During this conference, Dr. Guirakhoo will deliver an oral presentation entitled, A Novel Approach for Developing Single Dose and Safe Vaccines for Emerging Infectious Diseases.  In this talk, data for Ebola, Lassa and Zika vaccines, pathogens selected from three different families of viruses, will demonstrate GeoVax’s capability of developing safe and effective single-dose vaccines for many known emerging and re-emerging diseases, as well as for pathogens currently unknown to cause human disease (“Disease X”) with potential for a serious international epidemic. Many of these are included in the “Blueprint List of Priority Diseases” published by the World Health Organization (WHO); with explicit and urgent calls by WHO for accelerated research and development for vaccines and therapeutics. 

 About GeoVax

GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. GeoVax was the winner of the 2018 “Best Biotech” Vaccine Industry Excellence Awards, a finalist for the 2018 “Best Prophylactic Vaccine” Award for its Zika vaccine at the World Vaccine Congress, as well as a finalist for Pipelines of Promise at Buzz of Bio 2018. The Company’s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.

Contact: 

GeoVax Labs, Inc.

investor@geovax.com

678-384-7220

299982_GeoVaxLogo.jpg

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
17 Jan
PNDORA
Jeg vil bare henlede opmærksomheden paa Lars Christensens artikel omkring "Short Selling", direkte h..
36
18 Jan
I:SP500
  Hejsa    Jeg har igen vedlagt vores langsigtede konjunkturmodel med de ledende indikatorer i USA, ..
31
18 Jan
PNDORA
En stor tak til alle jer, der har givet mig en like (ialt 32). Det er dejligt at vide, at vi er mang..
18
15 Jan
AMBU-B
Det er nok klogere, at du passer paa Hedgefondene (shorterne) N/A NON DDB, som igen i dag staar for ..
16
13 Jan
VELO
Kan Veloxis få en markedsandel på 10% indenfor 12 måneder? Nedenfor vil jeg give mit bud.   1. Conve..
15
13 Jan
NOVO-B
Har hørt en lille fugl synge om, at en korrektion (måske) er ved at være afviklet efter 20% fald i f..
15
16 Jan
VWS
Din indsigt i verdensfirmaet Vestas er forbløffende!
14
18 Jan
ROV
Ja, og de to ovenstående kommentarer er i den grad med til at forringe og forsimple debatniveauet he..
13
17 Jan
PNDORA
Udfordringen er, at der hele tiden sker en bekræftigelse af at Pandoras fald er faldende uden nogle ..
13
15 Jan
VELO
Puha marc, det gør bare mere og mere ondt på dig at se kursen gå i vejret. Dit salg i 0,86 er tydeli..
13

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

Related news
22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Kitov Closes $6 Million Registered Direct Offering
2
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Danske Bank A/S – DNKEY
3
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Natural Health Trends Corporation – NHTC
4
MARRIOTT SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Marriott International, Inc. - MAR
5
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AxoGen, Inc. - AXGN

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
19 January 2019 15:33:19
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190108.3 - EUROWEB2 - 2019-01-19 16:33:19 - 2019-01-19 15:33:19 - 1000 - Website: OKAY